This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

A Roadmap to Key Pharmacologic Principles in Using Antipsychotics in the Treatment of Bipolar Disorder

Roy H. Perlis, MD

Published: July 31, 2008

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Article Abstract

On the basis of the National Comorbidity Survey Replication (NCS-R), it is estimated that bipolar I and II disorders may affect nearly 3% of the population (i.e., 5.7 million Americans), with the prevalence of subthreshold but still impairing bipolar presentations estimated to be even higher. Bipolar disorder is associated with significant functional impairment and elevated health care costs. Although unipolar depression appears to be over 6 times as prevalent as bipolar disorder, NCS-R data found that the costs of bipolar disorder to the U.S. workplace, estimated at $14.1 billion annually, were almost half the cost of lost productivity associated with unipolar depression.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: